Generation of antibody-derived polypeptides by polypeptide chain exchange
AssigneeHoffmann-La Roche Inc.
InventorsUlrich Brinkmann, Can Martin Buldun, Stefan Dengle, Steffen Dickopf, Guy Georges, Eike Hoffmann, Sabine Imhof-Jung, David Zilian
Life of this patent
Estimating the term…
Abstract
The present invention relates to a set of heterodimeric polypeptides and its uses, e.g. for generating multispecific antigen binders by polypeptide chain exchange.
Claims20
A set of heterodimeric precursor polypeptides comprising:
- a) a first heterodimeric precursor polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising the CH3 domain are associated with each other via the CH3 domains and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation,
- wherein the first heterodimeric precursor polypeptide comprises a first antigen binding moiety, wherein at least a part of the first antigen binding moiety is arranged on one of the two polypeptide chains comprising the CH3 domain, and
- b) a second heterodimeric precursor polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising the CH3 domain are associated with each other via the CH3 domains and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation,
- wherein the second heterodimeric precursor polypeptide comprises a second antigen binding moiety, wherein at least a part of the second antigen binding moiety is arranged on one of the two polypeptide chains comprising the CH3 domain;
- wherein
- A) either i) within the first heterodimeric precursor polypeptide the polypeptide chain comprising the CH3 domain comprising the knob mutation comprises at least a part of the first antigen binding moiety and within the second heterodimeric precursor polypeptide the polypeptide chain comprising the CH3 domain with the hole mutation comprises at least a part of the second antigen binding moiety, or ii) within the first heterodimeric precursor polypeptide the polypeptide chain comprising the CH3 domain comprising the hole mutation comprises at least a part of the first antigen binding moiety and within the second heterodimeric precursor polypeptide the polypeptide chain comprising the CH3 domain with the knob mutation comprises at least a part of the second antigen binding moiety;
- and wherein
- B) either
- i) the CH3 domain of the first heterodimeric precursor polypeptide comprising the knob mutation and the CH3 domain of the second heterodimeric precursor polypeptide comprising the hole mutation, or
- ii) the CH3 domain of the first heterodimeric precursor polypeptide comprising the hole mutation and the CH3 domain of the second heterodimeric precursor polypeptide comprising the knob mutation comprise the following amino acid substitutions, wherein the numbering is according to the Kabat numbering system:
- the CH3 domain with the hole mutation comprises at least one amino acid substitution selected from the group of
- replacement of S354 with a hydrophobic amino acid;
- replacement of D356 with a positively charged amino acid;
- replacement of E357 with a positively charged amino acid or with a hydrophobic amino acid;
- replacement of D356 with a positively charged amino acid, and replacement of E357 with a positively charged amino acid or with a hydrophobic amino acid;
- replacement of S364 with a hydrophobic amino acid;
- replacement of A368 with a hydrophobic amino acid;
- replacement of E392 with a negatively charged amino acid;
- replacement of T394 with a hydrophobic amino acid;
- replacement of D399 with a hydrophobic amino acid and replacement of S400 with a positively charged amino acid;
- replacement of D399 with a hydrophobic amino acid and replacement of F405 with a positively charged amino acid;
- replacement of V407 with a hydrophobic amino acid;
- and
- replacement of K409 with a negatively charged amino acid;
- and
- replacement of K439 with a negatively charged amino acid;
- the CH3 domain with the knob mutation comprises at least one amino acid substitution selected from the group of:
- replacement of Q347 with a positively charged amino acid, and replacement of K360 with a negatively charged amino acid;
- replacement of Y349 with a negatively charged amino acid;
- replacement of L351 with a hydrophobic amino acid, and replacement of E357 with a hydrophobic amino acid;
- replacement of S364 with a hydrophobic amino acid;
- replacement of W366 with a hydrophobic amino acid, and replacement of K409 with a negatively charged amino acid;
- replacement of L368 with a hydrophobic amino acid;
- replacement of K370 with a negatively charged amino acid;
- replacement of K370 with a negatively charged amino acid, and replacement of K439 with a negatively charged amino acid;
- replacement of K392 with a negatively charged amino acid;
- replacement of T394 with a hydrophobic amino acid;
- replacement of V397 with a hydrophobic amino acid;
- replacement of D399 with a positively charged amino acid, and replacement of K409 with a negatively charged amino acid;
- replacement of S400 with a positively charged amino acid;
- F405W;
- Y407W;
- and
- replacement of K439 with a negatively charged amino acid.
The set of heterodimeric polypeptides according to claim 1 or 2, wherein the CH3 domains indicated in b) comprise the following amino acid substitutions:
- the CH3 domain with the hole mutation comprises at least one amino acid substitution selected from the group of S354V, D356K, E357K, E357F, S364L, A368F, K392E, T394I, V407Y, K409E, K439E and a double mutation D399A S400K;
- and
- the CH3 domain with the knob mutation comprises at least one amino acid substitution selected from the group of Y349E, S364V, L368F, K370E, K392D, T394I, V397Y, S400K, F405W, Y407W, K349E, and double mutations Q347K K360E, L351F E357F, W366I K409E, and D399K K409E.
The set of heterodimeric polypeptides according to one of claims 1 to 4, wherein the CH3 domains indicated in b) comprise the following amino acid substitutions:
- the CH3 domain with the hole mutation comprises at least one amino acid substitution selected from the group of D356K, E357K, E357F, S364L, V407Y, K409E, and a double mutation D399A S400K;
- and
- the CH3 domain with the knob mutation comprises at least one amino acid substitution selected from the group of Y349E, K370E, K392D, T394I, V397Y, F405W, Y407W, K349E, and double mutations Q347K K360E, W366I K409E, and D399K K409E.
The set of heterodimeric polypeptides according to one of the preceding claims, wherein in case the CH3 domain with the knob mutation indicated in b) comprises a mutation E357K, the CH3 domain with the hole mutation indicated in b) does not comprise a mutation K370E;
- and wherein in case the CH3 domain with the knob mutation indicated in b) comprises a mutation D356K, the CH3 domain with the hole mutation indicated in b) does not comprise a mutation K439E.
The set of heterodimeric polypeptides according to one of the preceding claims, wherein either i) the CH3 domain comprising the knob mutation of the first heterodimeric precursor polypeptide comprises a cysteine mutation and the CH3 domain comprising the hole mutation of the second heterodimeric precursor polypeptide comprises a cysteine mutation, or ii) the CH3 domain comprising the hole mutation of the first heterodimeric precursor polypeptide comprises a cysteine mutation and the CH3 domain comprising the knob mutation of the second heterodimeric precursor polypeptide comprises a cysteine mutation.
The set of heterodimeric polypeptides according to one of the preceding claims, wherein the first antigen binding moiety and/or the second antigen binding moiety is an antibody fragment.
The set of heterodimeric polypeptides according to one of the preceding claims, wherein
- a) the first heterodimeric precursor polypeptide comprises:
- a first heavy chain polypeptide comprising a CH3 domain and a first antibody variable domain,
- a second heavy chain polypeptide comprising a CH3 domain, wherein the first heavy chain polypeptide and the second heavy chain polypeptide are associated with each other via the CH3 domains and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation;
- and
- a light chain polypeptide comprising a second antibody variable domain, wherein the first and second antibody variable domain together form a first antigen binding site specifically binding to a target antigen;
- and wherein
- b) the second heterodimeric precursor polypeptide comprises:
- a third heavy chain polypeptide comprising a CH3 domain and a third antibody variable domain,
- a fourth heavy chain polypeptide comprising a CH3 domain, wherein the third heavy chain polypeptide and the fourth heavy chain polypeptide are associated with each other via the CH3 domains and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation;
- and
- a light chain polypeptide comprising a fourth antibody variable domain, wherein the third and fourth antibody variable domain together form a second antigen binding site specifically binding to a target antigen;
- and wherein
- c) either i) the first heavy chain polypeptide comprises a CH3 domain comprising a knob mutation and the third heavy chain polypeptide comprises a CH3 domain comprising a hole mutation;
- or ii) the first heavy chain polypeptide comprises a CH3 domain comprising a hole mutation and the third heavy chain polypeptide comprises a CH3 domain comprising a knob mutation.
The set of heterodimeric polypeptides according to one of the preceding claims, wherein the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide comprise at least two polypeptide chains comprising from N- to C-terminal direction a hinge region, a CH2 domain and the CH3 domain.
The set of heterodimeric polypeptides according to one of the preceding claims, wherein the first heterodimeric precursor polypeptide comprises one polypeptide chain comprising a VL domain and the CH3 domain, and wherein the second heterodimeric precursor polypeptide comprises one polypeptide chain comprising a VH domain and the CH3 domain, wherein said VL domain and said VH domain specifically bind to an antigen when associated to a pair of a VH domain and a VL domain.
A heterodimeric polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising the CH3 domain are associated with each other via the CH3 domains and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation;
- wherein the heterodimeric polypeptide comprises a first antigen binding moiety, wherein at least a part of the first antigen binding moiety is arranged on one of the two polypeptide chains comprising the CH3 domain;
- and wherein the heterodimeric polypeptide comprises a second antigen binding moiety, wherein at least a part of the second antigen binding moiety is arranged on the other one of the two polypeptide chains comprising the CH3 domain;
- and
- wherein the CH3 domain with the hole mutation comprises at least one amino acid substitution selected from the group of:
- replacement of S354 with a hydrophobic amino acid;
- replacement of D356 with a positively charged amino acid;
- replacement of E357 with a positively charged amino acid or with a hydrophobic amino acid;
- replacement of D356 with a positively charged amino acid, and replacement of E357 with a positively charged amino acid or with a hydrophobic amino acid;
- replacement of S364 with a hydrophobic amino acid;
- replacement of A368 with a hydrophobic amino acid;
- replacement of E392 with a negatively charged amino acid;
- replacement of T394 with a hydrophobic amino acid;
- replacement of D399 with a hydrophobic amino acid and replacement of S400 with a positively charged amino acid;
- replacement of D399 with a hydrophobic amino acid and replacement of F405 with a positively charged amino acid;
- replacement of V407 with a hydrophobic amino acid;
- and
- replacement of K409 with a negatively charged amino acid;
- and
- replacement of K439 with a negatively charged amino acid;
- and wherein
- the CH3 domain with the knob mutation comprises at least one amino acid substitution selected from the group of:
- replacement of Q347 with a positively charged amino acid, and replacement of K360 with a negatively charged amino acid;
- replacement of Y349 with a negatively charged amino acid;
- replacement of L351 with a hydrophobic amino acid, and replacement of E357 with a hydrophobic amino acid;
- replacement of S364 with a hydrophobic amino acid;
- replacement of W366 with a hydrophobic amino acid, and replacement of K409 with a negatively charged amino acid;
- replacement of L368 with a hydrophobic amino acid;
- replacement of K370 with a negatively charged amino acid;
- replacement of K370 with a negatively charged amino acid, and replacement of K439 with a negatively charged amino acid;
- replacement of K392 with a negatively charged amino acid;
- replacement of T394 with a hydrophobic amino acid;
- replacement of V397 with a hydrophobic amino acid;
- replacement of D399 with a positively charged amino acid, and replacement of K409 with a negatively charged amino acid;
- replacement of S400 with a positively charged amino acid;
- F405W;
- Y407W;
- and
- replacement of K439 with a negatively charged amino acid.
The method according to claim 37, wherein the desired characteristic is selected from affinity and thermostability.
Dependencies are inferred from the claim text.